Fulgent Genetics (FLGT) Projected to Post Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Friday, May 2nd. Analysts expect Fulgent Genetics to post earnings of ($0.19) per share and revenue of $71.26 million for the quarter.

Fulgent Genetics Stock Down 0.8 %

FLGT traded down $0.16 during trading on Friday, hitting $18.88. The company's stock had a trading volume of 203,279 shares, compared to its average volume of 259,767. The business's 50 day simple moving average is $17.30 and its 200-day simple moving average is $18.14. The firm has a market cap of $582.75 million, a PE ratio of -3.42 and a beta of 1.36. Fulgent Genetics has a one year low of $14.57 and a one year high of $25.11.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on FLGT shares. Piper Sandler dropped their target price on shares of Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. StockNews.com upgraded shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a research report on Wednesday, March 5th.

Insiders Place Their Bets

In other news, CFO Paul Kim bought 100,000 shares of the stock in a transaction on Wednesday, March 5th. The stock was bought at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the completion of the purchase, the chief financial officer now directly owns 348,282 shares in the company, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 31.76% of the stock is owned by company insiders.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.